...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to NEWS - 

Batavia Biosciences Expands its Viral Vector and GMP Facilities to Accommodate Increasing Market Demand

| Print |
Monday, 16 October 2017 10:00 (UTC + 2)

BataviaBiosciences Logo

Leiden, The Netherlands, October 16, 2017 / B3C newswire / -- Today, Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands to accommodate the increasing market demand.

Chris Yallop, CSO Batavia Biosciences, explains: “Recent advances in cancer vaccines and gene therapy have given rise to a profound increase in the global demand for process development and clinical manufacturing of vector based products.”

The R&D facility in Medford, located just north of Cambridge (MA) allows Batavia Biosciences to extent the existing service portfolio in the United States, adding complete pre-clinical process development capabilities for viral vectors including AAV, Lentivirus, VSV and Adenovirus systems to its portfolio of CHO cell line generation and process development services for recombinant proteins and antibodies.

Expansion of its GMP clean room facilities in Leiden, the Netherlands better aligns the company’s GMP capacity with its increased R&D capability to further support the manufacturing of master cell banks and vaccine seed stocks.

Menzo Havenga, CEO Batavia Biosciences, concludes: “At Batavia Biosciences we are very much aware of the fact that the patient is waiting. With the completion of this investment, the company is now better positioned to maintain the speed and quality of bringing candidate biopharmaceuticals from bench to clinic.”

Pic1     Pic2

 For high resolution please click the image.


About Batavia Biosciences
Batavia Biosciences aims to significantly contribute to ease human suffering from disease by improving the success rate in the translation of candidate medicines from bench to clinic. We offer our novel technologies and in-depth knowhow to help our partners to complete preclinical phases in biopharmaceutical product development at higher speed, reduced costs and increased success. The company focuses on the early stages of product development including mammalian cell line generation, upstream process development (mammalian & microbial), purification development, product characterization and clinical manufacturing. Headquartered in Leiden, The Netherlands, with a US-based facility in Woburn, Massachusetts, and offices in Hong Kong, Batavia Biosciences is privileged to have strong strategic partners worldwide.


Contact
Vincent Franssen, Commercial Director
+31 88 995 06 15
This e-mail address is being protected from spambots. You need JavaScript enabled to view it